(RTTNews) - Shares of Genetic Technologies Ltd. (GENE) shares surged over 50% on Wednesday morning. The molecular diagnostics company said it has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia.
GENE is currently trading at $3.51, up $1.25 or 55.31%, on the Nasdaq.
Genetic Technologies is developing a Polygenic Risk Score test for COVID-19, which may enable an assessment of risk of an individual developing a serious disease should they contract the COVID-19 virus. The test is intended to predict 'disease severity' using a combination of genetic and clinical information.
Genetic Technology expects to make its data pack for the COVID-19 Severity Risk Test available to global labs.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
